CTCFL Antibody

1. aberrant expression of BORIS inhibits apoptosis, promotes proliferation, and attenuates the sensitivity of colorectal cancer cells to 5-FU treatment. PMID: 28098226
2. These findings highlight the role of intragenic DNA methylation and DNA binding protein BORIS in cancer-specific splicing and its role in tumorigenesis. PMID: 29073069
3. The CCCTC-binding factor plays critical roles in genome topology and function, increased risk of carcinogenicity, and potential of lung cancer-specific mediations. Chromosome reposition in lung cancer can be regulated by CCCTC binding factor PMID: 27840277
4. These data provide information on the organization of the BORIS promoter region and gene regulation in normal and cancer cells. In addition, the study proposes that specific alleles of the BORIS-MS2 region could be used to identify the risk for lung cancer. PMID: 27416782
5. the results indicate that the CT antigen BORIS sf6 is specifically expressed in cervical cancer stem-like cells and cancer-initiating cells PMID: 26849232
6. BORIS is associated with the cancer stem cell-like traits of human liver cancer cells through the epigenetic regulation of OCT4. PMID: 28645561
7. In this study, the methylation status of BORIS was tested by methylation specific polymerase chain reaction in human hepatocarcinoma (HCC) cell lines and 43 pairs of tissue specimens. Frequently demethylation of BORIS in HCC was significantly higher than that in the paired adjacent non-tumor tissues (P=0.019), and it was correlated with tumor size (P=0.025) and clinical TNM stage (P=0.035). PMID: 28764977
8. Effectively controlling BORIS/CTCFL levels can inhibit disease establishment and hence can be considered as a potent target for cancer therapy PMID: 28104398
9. BORIS is associated with cancer stem cell-enriched populations of several epithelial tumor cells and the different phenotypes depend on the origin of tumor cells. PMID: 26185996
10. Data found that BORIS and CTCF expression in low-grade squamous intraepithelial lesions and invasive cervical carcinoma is higher than in normal samples. The possible utility of BORIS and CTCF as biomarkers in cervical neoplasm requires further analysis. PMID: 26125810
11. Differential regulation of MAGE-A1 promoter activity by BORIS and Sp1, both interacting with the TATA binding protein. PMID: 25363021
12. High BORIS transcript variants are associated with laryngeal squamous cell carcinomas. PMID: 24563233
13. CTCFL/BORIS was amongst the top ranked genes differentially expressed between endometrioid and non-endometrioid tumors, and increasing mRNA level of CTCFL/BORIS was highly significantly associated with poor survival. PMID: 24658009
14. The serum levels of MAGE-A and BORIS mRNA, as well as let-7b were significantly higher in patients. PMID: 24983365
15. results provide novel insights into the determinants of NOTCH3 overexpression in cancer cells, by revealing a key role for BORIS as the main mediator of transcriptional deregulation of NOTCH3 PMID: 24984200
16. BORIS is an RNA-binding protein that associates with polysomes. PMID: 24279897
17. Neither the MTHFR polymorphism, nor CTCFL mutations explain a pattern of sperm hypomethylation at paternally imprinting loci PMID: 23955684
18. The ability of BORIS to activate the androgen receptor gene indicates BORIS involvement in the growth and development of prostate tumors. PMID: 24123052
19. The expression of BORIS isoform families in normal ovary (NO) and epithelial ovarian cancer. PMID: 23390377
20. CTCF and BORIS suppressed breast cancer growth; findings provide further evidence that CTCF behaves as a tumor suppressor, and show BORIS has a similar growth inhibitory effect in vitro and in vivo PMID: 23553099
21. our study has shown for the first time that BORIS is expressed in hepatocellular carcinoma (HCC) tissues, and its expression significantly correlates with poor prognosis and cd90 expression. PMID: 23237599
22. BORIS induces demethylation of the SBSN CpG island and disruption and activation of chromatin around the SBSN transcription start site, resulting in an increase in SBSN expression. PMID: 22792300
23. down-regulation of endogenous BORIS by specific shRNAs inhibited both RNA transcription and cell cycle progression. The results altogether suggest a role for BORIS in coordinating S phase events with mitosis. PMID: 22724006
24. BORIS may be a useful biomarker for prognostic diagnosis of ESCC patients and a potential target for treatment including by BORIS-specific immunotherapy and molecular target therapy. PMID: 22676270
25. This review summarizes what is known about BORIS regarding its expression, structure, and function. PMID: 22168535
26. Transcription of the ferT gene in colon cancer cells was found to be driven by an intronic promoter residing in intron 10 of the fer gene and to be regulated by the Brother of the Regulator of Imprinted Sites (BORIS) transcription factor. PMID: 22223638
27. a significant up-regulation of BORIS (p<0.001) and TSHZ1 transcripts (p<0.05) for JAs compared to nasal mucosa. PMID: 21874228
28. These findings show that BORIS expression is more widespread than previously believed, and suggest a role for BORIS in nucleolar function. PMID: 21811597
29. BORIS-MS2 alleles are transmitted through meiosis following Mendelian inheritance, which suggests that this polymorphic minisatellite could be a useful marker for paternity mapping and DNA fingerprinting. PMID: 21495859
30. BORIS positively regulates these CTAs by binding and inducing a shift to a more open chromatin conformation with promoter demethylation PMID: 21558405
31. Data show that the BORIS/CTCF mRNA expression ratio is closely associated with DNA hypomethylation and confers poor prognosis in EOC. PMID: 21296871
32. The activity of CTCF in controlling Rb2/p130 gene expression is impaired by BORIS, which by binding to the Rb2/p130 gene could trigger changes in the chromatin asset established by CTCF affecting CTCF regulatory activity on Rb2/p130 transcription. PMID: 21325284
33. Data suggest that the BORIS gene is involved in a range of functionally important aspects of both normal gametogenesis and cancer development. PMID: 21079786
34. The short rare alleles of BORIS-MS2 could be used to identify the risk for breast cancer in young patients. PMID: 21034534
35. BORIS (CTCFL) is not expressed in most human breast cell lines and high grade breast carcinomas PMID: 20305816
36. Expression of the cancer-germline (CG) (or cancer-testis) antigen gene BORIS/CTCFL has been proposed to mediate activation of CG antigen genes in cancer. PMID: 20649179
37. the C-terminal fragment of CTCFL predominantly consists of extended and unordered content. PMID: 20438700
38. As no mutations were detected at CTCFL in the patients examined, we conclude that genetic alterations of CTCFL are not responsible for the SRS hypomethylation. PMID: 19675668
39. Data indicate that reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter mediates epigenetic regulation of this CT gene in lung cancer cells. PMID: 16140944
40. The lack of hypomethylation in the CFCFL promoter reinforces evidence that 'genome-wide' hypomethylation is not random. PMID: 16854382
41. BORIS represents a new class of cancer biomarkers different from those currently used in medical practice. PMID: 17062669
42. we detected a high frequency of BORIS expression in uterine cancers. PMID: 17363524
43. The expression of BORIS antigen is much stronger in breast cancer than that in benign breast disease and normal breast tissues, which indicate that BORIS may be involved in the pathogenesis of the breast cancer. PMID: 17428394
44. Activation of BORIS is associated with melanoma PMID: 17957795
45. Alternative promoter usage generated at least five alternatively spliced BORIS mRNAs with different half-lives determined by varying 5'-UTRs. PMID: 17962299
46. These data establish promoter DNA hypomethylation as a mechanism leading to BORIS expression in human ovarian cancer. PMID: 18095639
47. The ability of BORIS to activate promoters of the RP and ER genes points towards possible involvement of BORIS in the establishment, progression and maintenance of breast tumours. PMID: 18195709
48. Chromatin immunoprecipitation analysis of the BAG-1 promoter in DNMT1-overexpressing or DNMT3B-overexpressing colon cells show a permissive chromatin status assoscsiated with DNA binding of BORIS. PMID: 18413740
49. Differential expression of the cancer/testis gene BORIS in human preimplantation development. PMID: 18467432
50. CTCFL/BORIS is a methylation-independent DNA-binding protein that preferentially binds to the paternal H19 differentially methylated region PMID: 18632606

Show More

Hide All

HGNC: 16234

OMIM: 607022

KEGG: hsa:140690

STRING: 9606.ENSP00000243914

UniGene: Hs.131543